Strong growth expectation. We highlight that the company recorded notable revenue growth in 17Q3 (+24.9% YoY in RMB terms) beyond our expectation. We attribute this to 1) sales hike and rising share of innovative drugs; 2) Caffeine segment reported fast growth and newly-acquired glucose business made more contribution; 3) Vitamin C sales continued to climb. GPM increased by 8.3ppts (17Q3 58.46%, 16Q3 50.17%) due to share of innovative drugs rose which enjoyed higher profit margin. The management expect bottom line to maintain 20%-30% growth in 17E/18E.